• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc.

    10/18/24 8:38:16 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IOVA alert in real time by email
    SC 13G/A 1 Iovance_Biothera_Inc.htm SCHEDULE 13G Amendment No. 15

     

      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )*
     

    IOVANCE BIOTHERAPEUTICS INC

    (Name of Issuer)
     

    COMMON STOCK

    (Title of Class of Securities)
     

    462260100

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 5 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    462260100 13G Page 2 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    STATE STREET CORPORATION

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 04-2456637

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    MA

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    12,445,899

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    13,201,978

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    13,201,978.00

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.4%

    12

    TYPE OF REPORTING PERSON

    HC

             

     

     

     

    462260100 13G Page 3 of 5 Pages

     

    Item 1(a). NAME OF ISSUER
       
      IOVANCE BIOTHERAPEUTICS INC

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
       
      999 SKYWAY ROAD SUITE 150 SAN CARLOS CA 94070 UNITED STATES

     

    Item 2(a). NAME OF PERSON FILING
       
     

    STATE STREET CORPORATION

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES

     

    Item 2(c). CITIZENSHIP
       
      MA

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       
      COMMON STOCK

     

    Item 2(e). CUSIP NUMBER
       
      462260100

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§240.13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

    STATE STREET CORPORATION (a) Broker or dealer registered under Section 15 of the Act;
      (b) Bank as defined in Section 3(a)(6) of the Act;
      (c) Insurance company as defined in Section 3(a)(19) of the Act;
      (d) Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f)

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

      (g) X

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h)

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i)

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K).
      If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     

    462260100 13G Page 4 of 5 Pages

     

    Item 4. OWNERSHIP
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a) Amount beneficially owned: 13,201,978.00  
      (b) Percent of class: 4.4%  
      (c) Number of shares as to which the person has:    
             
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote 12,445,899
        (iii) Sole power to dispose or to direct the disposition of 0
        (iv) Shared power to dispose or to direct the disposition of 13,201,978
             
      Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following
      ý
      Instruction: Dissolution of a group requires a response to this item.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      NOT APPLICABLE

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      SSGA FUNDS MANAGEMENT, INC. (IA) STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA) STATE STREET GLOBAL ADVISORS LIMITED (IA) STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA) STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED (IA) STATE STREET GLOBAL ADVISORS, LTD. (IA)

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      NOT APPLICABLE

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      NOT APPLICABLE

     

    Item 10. CERTIFICATION

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11
       

     

     

     

    462260100 13G Page 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: October 14, 2024

     

       
         
         
        ELIZABETH SCHAEFER, SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
         
         

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    Get the next $IOVA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IOVA

    DatePrice TargetRatingAnalyst
    7/15/2025$1.00Neutral → Sell
    Goldman
    5/16/2025$2.00Buy → Neutral
    UBS
    5/12/2025Buy → Hold
    Truist
    5/9/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    10/24/2024$17.00Buy
    UBS
    7/29/2024$19.00 → $10.00Overweight → Neutral
    Piper Sandler
    11/20/2023$12.00Buy
    Goldman
    9/18/2023$40.00 → $18.00Overweight
    Barclays
    More analyst ratings

    $IOVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Roche Corleen M.

    4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

    8/8/25 4:06:19 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Roche Corleen M.

    3 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

    8/8/25 4:05:17 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Rosinack Matthew W. claimed ownership of 89,129 shares (SEC Form 3)

    3 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

    7/10/25 4:05:15 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IOVA
    SEC Filings

    View All

    Iovance Biotherapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

    8/19/25 4:47:37 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Iovance Biotherapeutics Inc.

    10-Q - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

    8/7/25 5:16:03 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Iovance Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

    8/7/25 4:06:34 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IOVA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IOVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $IOVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Iovance Biotherapeutics downgraded by Goldman with a new price target

    Goldman downgraded Iovance Biotherapeutics from Neutral to Sell and set a new price target of $1.00

    7/15/25 8:37:18 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Iovance Biotherapeutics downgraded by UBS with a new price target

    UBS downgraded Iovance Biotherapeutics from Buy to Neutral and set a new price target of $2.00

    5/16/25 8:01:50 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Iovance Biotherapeutics downgraded by Truist

    Truist downgraded Iovance Biotherapeutics from Buy to Hold

    5/12/25 8:21:43 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- USA News Group News Commentary – Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with oncology ventures securing hundreds of millions in funding so far in 2025. The Senate's recent restoration of $15 million for the Pancreatic Cancer Research Program (PCARP) was a win, yet its earlier elimination underscored the fragility of public support. Against this backdrop, investors are zeroing in on companies with standout science, solid pipelines, and clear regulatory strategies, including Onc

    8/14/25 12:22:00 PM ET
    $FATE
    $INO
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025

    SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and first half 2025 financial results and corporate updates on Thursday, August 7, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on August 7, 2025, at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/cgjzdfym. The live and archived webcast can be accessed i

    7/24/25 4:05:00 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on July 17, 2025 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 138,190 shares of Iovance's common stock to 20 new, non-executive employees. The awards were granted under Iovance's Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022, March 13, 202

    7/18/25 5:15:00 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IOVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Kirby Daniel Gordon bought $55,200 worth of shares (30,000 units at $1.84) (SEC Form 4)

    4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

    6/6/25 4:05:31 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Regulatory Officer Puri Raj K. bought $9,743 worth of shares (5,600 units at $1.74), increasing direct ownership by 3% to 206,852 units (SEC Form 4)

    4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

    5/27/25 4:06:43 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Interim CEO & General Counsel Vogt Frederick G bought $42,250 worth of shares (25,000 units at $1.69), increasing direct ownership by 7% to 374,646 units (SEC Form 4)

    4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

    5/16/25 4:05:18 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IOVA
    Financials

    Live finance-specific insights

    View All

    Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025

    SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and first half 2025 financial results and corporate updates on Thursday, August 7, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on August 7, 2025, at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/cgjzdfym. The live and archived webcast can be accessed i

    7/24/25 4:05:00 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025

    SAN CARLOS, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2025 financial results and corporate updates on Thursday, May 8, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on May 8, 2025 at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/wi5b4tnt. The live and archived webcast can be accessed in the Investors sectio

    5/2/25 4:01:39 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025

    SAN CARLOS, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its fourth quarter and full year 2024 financial results and corporate updates on Thursday, February 27, 2025. Fourth Quarter and Full Year 2024 Audio WebcastManagement will host a live audio webcast to discuss these results and provide a corporate update on February 27, 2025 at 4:30 p.m. EST. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/hw2g9axf/. Upcoming

    2/18/25 4:01:00 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IOVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc.

    SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

    11/14/24 4:50:30 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc.

    SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

    10/18/24 8:38:16 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Iovance Biotherapeutics Inc. (Amendment)

    SC 13D/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

    3/19/24 5:19:45 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IOVA
    Leadership Updates

    Live Leadership Updates

    View All

    Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

    SAN CARLOS, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Corleen Roche as Chief Financial Officer (CFO), effective August 6th, 2025. "I am pleased to welcome Corleen to Iovance at such an important stage in our first commercial launch," said Frederick G. Vogt, Ph.D., J.D., Interim Chief Executive Officer, President and General Counsel. "Corleen's experience in executive financial leadership roles and multiple product launches will be in

    7/15/25 7:30:49 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy

    SAN CARLOS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Marc. R Theoret, M.D. to assume the newly created position of Senior Vice President, Regulatory Strategy, where he will focus on clinical regulatory strategy for Iovance's pipeline. Effective immediately, Dr. Theoret will report to Dr. Raj K. Puri, M.D., Ph.D., Chief Regulatory Officer. For more than 15 years, Dr. Theoret held various roles in the United States Food and Drug Administrat

    7/10/25 4:01:00 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Traws Pharma Announces Management Updates

    Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assum

    3/28/25 4:30:00 PM ET
    $IKNA
    $IOVA
    $TRAW
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations